Tirzepatide slowed the progression of chronic kidney disease in patients with type 2 diabetes with increased cardiovascular risk | News

Investigative analysis of SURPASS-4 test data for renal function with tirzepatide versus insulin glargine

NEW ORLEAN, June 3, 2022 / PRNewswire / – A pre-updated research analysis in the SURPASS-4 study showed that tirzepatide, a new drug used once a week to treat diabetes, improves kidney function in adults with type 2 diabetes who have an increased risk of cardiovascular disease. SURPASS-4 was part of SURPASS’s global clinical development program for tirzepatide Eli Lilly and Company. Conclusions were presented at 82and Scientific sessions of the American Diabetes Association® (ADA).

Chronic kidney disease (CKD) is a common complication of type 2 diabetes, a condition that worsens over time and can lead to kidney failure. З every third adult in diabetes mellitus affected by CKD, there is an unmet need for new treatments to reduce the development and progression of CKD in patients with diabetes.

This pre-specific SURPASS-4 study analyzed the progression to predetermined renal endpoints between tirzepatide and titrated daily insulin glargine (iGlar). The rate of decreased renal function and urinary albumin excretion were used as results. The clinical endpoint was a decrease of 40% or more from baseline, renal death, progression to end-stage renal disease, analyzed with new onset macroalbuminuria as an additional component and without it. A total of 1995 patients were registered, mean age 63.6 years and blood glucose (blood sugar), or A1C, 8.5%. Patients were observed for up to 104 weeks.

The results show that participants in tirzepatide experienced fewer renal complications compared to those who received insulin. In particular, rates of new-onset macroalbuminuria, a signal of poor renal outcome, were significantly lower in the tirzepatide group (hazard ratio = 0.41). In addition, in individuals with type 2 diabetes and high cardiovascular risk, tirzepatide reduced the rate of renal loss and the amount of protein excreted in the urine, which is a marker of the risk of CKD progression.

“With these SURPASS-4 research results, we are seeing for the first time the results of combined GIP / GLP-1 receptor agonists on renal function in patients with type 2 diabetes,” said HJL Heerspink, PhD, PharmD, University Medical Center Groningen, The Netherlands. “The findings will be of interest to doctors treating people with diabetes who may have chronic kidney disease.”

Tirzepatide is a new agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which is administered once a week, combining the actions of GIP and GLP-1 incretins into one new class molecule. drugs to treat type 2 diabetes. In the United States, tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Details of the research presentation:

Dr. Hida L. Herspink and the researchers presented the test results during the session listed below:

For more information, please contact the ADA Scientific Sessions Media Group on-site at the Ernest N. Morial Convention Center from June 3 to 7 at 504-670-4902 or by email at SciSessionsPress@diabetes.org.

About ADA research sessions

ADA 82and Scientific Sessions, the world’s largest scientific meeting on diabetes research, prevention and care, will be a hybrid event to be held on June 3-7, 2022 at the Ernest N. Moral Conference Center in New Orleans, Louisiana. Leading physicians, scientists, and health professionals from around the world will present cutting-edge research, treatment recommendations, and advances in diabetes treatment. We want to return to safe personal engagement and communication with colleagues while listening to the latest scientific advances and groundbreaking research presentations. Learn more and sign up at sciencesessions.diabetes.org and join the Scientific Sessions conversation on social media via # ADA2022.

About the American Diabetes Association

The American Diabetes Association (ADA) is the leading voluntary health organization in the country, fighting to overcome the diabetes epidemic and help people living with diabetes develop. For 81 years, the ADA has managed discoveries and research to treat, manage and prevent diabetes, working tirelessly on treatment. Through advocacy, program development, and education, we are committed to improving the quality of life for the more than 133 million Americans living with diabetes or pre-diabetes. Diabetes has united us. What we do next will make us connected for life. To learn more or get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish FacebookAmerican Diabetes Association), LinkedInAmerican Diabetes Association), Twitter@AmDiabetesAssn), and Instagram@AmDiabetesAssn).

Contact: Daisy Diaz504-670-4902


See original content for multimedia downloads:https://www.prnewswire.com/news-releases/tirzepatide-slowed-progression-of-chronic-kidney-disease-in-patients-with-type-2-diabetes-with-increased-cardiovascular-risk-301561281. html

SOURCE of the American Diabetes Association

Source link